These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 22591213)

  • 1. Selection of excipient, solvent and packaging to optimize the performance of spray-dried formulations: case example fenofibrate.
    Hugo M; Kunath K; Dressman J
    Drug Dev Ind Pharm; 2013 Feb; 39(2):402-12. PubMed ID: 22591213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preparation and in vitro/in vivo evaluation of fenofibrate nanocrystals.
    Zuo B; Sun Y; Li H; Liu X; Zhai Y; Sun J; He Z
    Int J Pharm; 2013 Oct; 455(1-2):267-75. PubMed ID: 23876497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High drug load, stable, manufacturable and bioavailable fenofibrate formulations in mesoporous silica: a comparison of spray drying versus solvent impregnation methods.
    Hong S; Shen S; Tan DC; Ng WK; Liu X; Chia LS; Irwan AW; Tan R; Nowak SA; Marsh K; Gokhale R
    Drug Deliv; 2016; 23(1):316-27. PubMed ID: 24853963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of spray drying and milling in the production of amorphous dispersions of sulfathiazole/polyvinylpyrrolidone and sulfadimidine/polyvinylpyrrolidone.
    Caron V; Tajber L; Corrigan OI; Healy AM
    Mol Pharm; 2011 Apr; 8(2):532-42. PubMed ID: 21323367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous and scalable process for water-redispersible nanoformulation of poorly aqueous soluble APIs by antisolvent precipitation and spray-drying.
    Hu J; Ng WK; Dong Y; Shen S; Tan RB
    Int J Pharm; 2011 Feb; 404(1-2):198-204. PubMed ID: 21056643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative study of spray-dried and freeze-dried hydrocortisone/polyvinyl pyrrolidone solid dispersions.
    Dontireddy R; Crean AM
    Drug Dev Ind Pharm; 2011 Oct; 37(10):1141-9. PubMed ID: 21615280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dissolution enhancement of fenofibrate by micronization, cogrinding and spray-drying: comparison with commercial preparations.
    Vogt M; Kunath K; Dressman JB
    Eur J Pharm Biopharm; 2008 Feb; 68(2):283-8. PubMed ID: 17574403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel nanomatrix system consisted of colloidal silica and pH-sensitive polymethylacrylate improves the oral bioavailability of fenofibrate.
    Jia Z; Lin P; Xiang Y; Wang X; Wang J; Zhang X; Zhang Q
    Eur J Pharm Biopharm; 2011 Sep; 79(1):126-34. PubMed ID: 21658449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced oral bioavailability of fenofibrate using polymeric nanoparticulated systems: physicochemical characterization and in vivo investigation.
    Yousaf AM; Kim DW; Oh YK; Yong CS; Kim JO; Choi HG
    Int J Nanomedicine; 2015; 10():1819-30. PubMed ID: 25784807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach.
    Fei Y; Kostewicz ES; Sheu MT; Dressman JB
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1274-84. PubMed ID: 23500116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spray drying from organic solvents to prepare nanoporous/nanoparticulate microparticles of protein: excipient composites designed for oral inhalation.
    Ní Ógáin O; Tajber L; Corrigan OI; Healy AM
    J Pharm Pharmacol; 2012 Sep; 64(9):1275-90. PubMed ID: 22881440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mesoporous silica-based dosage forms improve release characteristics of poorly soluble drugs: case example fenofibrate.
    Dressman JB; Herbert E; Wieber A; Birk G; Saal C; Lubda D
    J Pharm Pharmacol; 2016 May; 68(5):634-45. PubMed ID: 26255860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparation and evaluation of raloxifene-loaded solid dispersion nanoparticle by spray-drying technique without an organic solvent.
    Tran TH; Poudel BK; Marasini N; Chi SC; Choi HG; Yong CS; Kim JO
    Int J Pharm; 2013 Feb; 443(1-2):50-7. PubMed ID: 23318367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anomalous properties of spray dried solid dispersions.
    Al-Obaidi H; Brocchini S; Buckton G
    J Pharm Sci; 2009 Dec; 98(12):4724-37. PubMed ID: 19455622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation of fenofibrate immediate-release tablets involving wet grinding for improved bioavailability.
    Zhang L; Chai G; Zeng X; He H; Xu H; Tang X
    Drug Dev Ind Pharm; 2010 Sep; 36(9):1054-63. PubMed ID: 20818965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipidic dispersion to reduce food dependent oral bioavailability of fenofibrate: In vitro, in vivo and in silico assessments.
    O'Shea JP; Faisal W; Ruane-O'Hora T; Devine KJ; Kostewicz ES; O'Driscoll CM; Griffin BT
    Eur J Pharm Biopharm; 2015 Oct; 96():207-16. PubMed ID: 26215636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accelerated ketoprofen release from polymeric matrices: importance of the homogeneity/heterogeneity of excipient distribution.
    Gue E; Willart JF; Muschert S; Danede F; Delcourt E; Descamps M; Siepmann J
    Int J Pharm; 2013 Nov; 457(1):298-307. PubMed ID: 24076398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fabrication of fenofibrate nanocrystals by probe sonication method for enhancement of dissolution rate and oral bioavailability.
    Ige PP; Baria RK; Gattani SG
    Colloids Surf B Biointerfaces; 2013 Aug; 108():366-73. PubMed ID: 23602990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigating the effect of moisture protection on solid-state stability and dissolution of fenofibrate and ketoconazole solid dispersions using PXRD, HSDSC and Raman microscopy.
    Kanaujia P; Lau G; Ng WK; Widjaja E; Schreyer M; Hanefeld A; Fischbach M; Saal C; Maio M; Tan RB
    Drug Dev Ind Pharm; 2011 Sep; 37(9):1026-35. PubMed ID: 21417604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The conflict between in vitro release studies in human biorelevant media and the in vivo exposure in rats of the lipophilic compound fenofibrate.
    Do TT; Van Speybroeck M; Mols R; Annaert P; Martens J; Van Humbeeck J; Vermant J; Augustijns P; Van den Mooter G
    Int J Pharm; 2011 Jul; 414(1-2):118-24. PubMed ID: 21596119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.